Jazz Pharmaceuticals (JAZZ) Misses Q3 EPS by 4c, Updates FY Guidance
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $109.27 +2.03%
EPS Growth %: +6.3%
Financial Fact:
Total revenues: 374.18M
Today's EPS Names:
ESCA, LICT, NKSH, More
EPS Growth %: +6.3%
Financial Fact:
Total revenues: 374.18M
Today's EPS Names:
ESCA, LICT, NKSH, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $2.52, $0.04 worse than the analyst estimate of $2.56. Revenue for the quarter came in at $340.9 million versus the consensus estimate of $348.15 million.
Jazz Pharmaceuticals sees FY2015 EPS of $9.45-$9.60, versus the consensus of $9.67. Jazz Pharmaceuticals sees FY2015 revenue of $1.32-1.34 million, versus the consensus of $1.36 million.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance
- BayCom Corp (BCML) Misses Q1 EPS by 4c
- Chemung Financial (CHMG) Tops Q1 EPS by 44c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
